If you read peptide or GLP-1 news, you keep hitting “503A” and “503B.” They are the two legal lanes for compounding, and the difference explains most of what you read. Here it is in plain English.

503A: traditional pharmacy compounding

A 503A pharmacy prepares a medication for an individual patient with a valid prescription — a custom dose, a different form, an allergy-friendly version. It is patient-specific and smaller-scale.

503B: outsourcing facilities

A 503B “outsourcing facility” can make larger batches, sometimes without a patient-specific prescription, and is held to stricter manufacturing standards (closer to a drug factory). Hospitals and clinics often buy from them.

The part that actually matters: the “bulks lists”

Each lane has a list of bulk drug substances a pharmacy is allowed to compound from. A substance has to be eligible to be on that list. That is why every peptide headline is really about a list: the July 2026 vote was about the 503A bulks list for peptides like BPC-157, while the GLP-1 fight is about the 503B bulks list for semaglutide and tirzepatide.

When the news says a peptide was “recommended for the list,” this is the list — and “recommended” still isn’t “on it.”

Why it matters to you

Whether something can be legally compounded — and by whom — depends on which lane and which list it falls under, plus a valid prescription. A licensed provider or pharmacist can tell you what actually applies to your situation.